TG Therapeutics (NASDAQ:TGTX) Stock Crosses Above 200-Day Moving Average – Time to Sell?

TG Therapeutics, Inc. (NASDAQ:TGTX)’s stock price crossed above its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $46.76 and traded as high as $54.75. TG Therapeutics shares last traded at $53.91, with a volume of 1,545,883 shares trading hands.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. B. Riley Financial upped their target price on shares of TG Therapeutics from $55.00 to $86.00 and gave the stock a “buy” rating in a research note on Monday, July 27th. JPMorgan Chase & Co. boosted their price objective on shares of TG Therapeutics from $65.00 to $72.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Weiss Ratings raised TG Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, September 21st. Jefferies Financial Group reiterated a “buy” rating and set a $83.00 target price on shares of TG Therapeutics in a research note on Monday, June 22nd. Finally, Bank of America lifted their target price on TG Therapeutics from $17.00 to $20.00 and gave the stock an “underperform” rating in a report on Tuesday, July 7th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $63.00.

TG Therapeutics Price Performance

The company has a quick ratio of 3.72, a current ratio of 4.27 and a debt-to-equity ratio of 1.23. The firm’s fifty day moving average price is $53.62 and its two-hundred day moving average price is $46.91. The stock has a market capitalization of $8.11 billion, a PE ratio of 19.32, a PEG ratio of 2.31 and a beta of 1.80.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.26). The company had revenue of $240.34 million during the quarter, compared to the consensus estimate of $229.77 million. TG Therapeutics had a return on equity of 73.49% and a net margin of 55.22%.The company’s revenue for the quarter was up 70.2% on a year-over-year basis. During the same period last year, the firm posted $0.17 EPS. On average, equities analysts predict that TG Therapeutics, Inc. will post 0.92 earnings per share for the current year.

Insider Activity at TG Therapeutics

In related news, Director Laurence Charney sold 5,000 shares of the company’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $54.96, for a total transaction of $274,800.00. Following the completion of the sale, the director owned 168,640 shares in the company, valued at approximately $9,268,454.40. This represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 8.87% of the stock is owned by insiders.

Institutional Investors Weigh In On TG Therapeutics

Large investors have recently made changes to their positions in the company. EverSource Wealth Advisors LLC boosted its holdings in shares of TG Therapeutics by 51.9% in the first quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 365 shares during the last quarter. Pingora Partners LLC raised its position in TG Therapeutics by 31.2% in the fourth quarter. Pingora Partners LLC now owns 2,100 shares of the biopharmaceutical company’s stock worth $63,000 after acquiring an additional 500 shares during the period. Harbor Investment Advisory LLC purchased a new position in shares of TG Therapeutics during the 2nd quarter worth $96,000. Allworth Financial LP purchased a new position in shares of TG Therapeutics during the 2nd quarter worth $128,000. Finally, KBC Group NV grew its position in shares of TG Therapeutics by 28.9% during the 1st quarter. KBC Group NV now owns 5,335 shares of the biopharmaceutical company’s stock valued at $177,000 after acquiring an additional 1,195 shares during the period. 58.58% of the stock is currently owned by institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for B-cell-mediated diseases, including multiple sclerosis and B-cell malignancies. The company’s research and development activities center on antibody-based therapies designed to target B cells and related immune pathways.

TG Therapeutics’ principal marketed product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved in the United States for the treatment of adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.